SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 1.47 |
| Enterprise Value ($M) | -0.00 |
| Book Value ($M) | -0.06 |
| Book Value / Share | -0.00 |
| Price / Book | -24.56 |
| NCAV ($M) | -1.39 |
| NCAV / Share | -0.05 |
| Price / NCAV | -1.06 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -3.44 |
| Return on Assets (ROA) | -1.44 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.35 |
| Current Ratio | 1.42 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 5.39 |
| Assets | 6.72 |
| Liabilities | 6.78 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 9.18 |
| Operating Income | -16.28 |
| Net Income | -13.09 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Dilutive Effect Of Stock Options | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -12.11 |
| Cash from Investing | -0.04 |
| Cash from Financing | 11.06 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Schuler Jack W | 14.70 | 41.70 | |
| 13G/A | Armistice Capital, Llc | 4.99 | -36.24 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Similar Companies | |
|---|---|
| ATXI – Avenue Therapeutics, Inc. | AVRW – Avenir Wellness Solutions, Inc. |
| AVVH – AVVAA World Health Care Products, Inc. | AXIM – AXIM Biotechnologies, Inc. |
| AZNCF – AstraZeneca PLC |
Financial data and stock pages provided by
Fintel.io